Bone disease and HIV infection.

Area of Science:

• Bone metabolism and endocrinology
• Infectious diseases
• Virology

Background:

• Bone demineralization is common in human immunodeficiency virus (HIV)-infected individuals, raising concerns about future fragility fractures.
• Despite high prevalences of osteopenia and osteoporosis, recent longitudinal studies suggest bone loss does not accelerate beyond the initial phase of antiretroviral therapy (ART).

Purpose of the Study:

• To review current understanding of HIV-associated bone loss mechanisms.
• To summarize recent clinical trial findings on treating bone loss in HIV patients.
• To provide guidance on bone disease screening and treatment for HIV-infected individuals.

Main Methods:

• Review of recent longitudinal studies on bone loss in HIV patients on ART.
• Analysis of clinical trial data on bone disease treatments in HIV-infected populations.
• Synthesis of current knowledge on HIV, ART, and immune factors affecting bone turnover.

Main Results:

• While osteopenia and osteoporosis are prevalent, accelerated bone loss during long-term ART is generally not observed beyond the initial treatment period.
• Ongoing research continues to elucidate the complex interplay of HIV infection, ART, and immune factors in bone metabolism.
• Recent clinical trials have investigated the safety and efficacy of various treatments for bone loss in HIV-infected patients.

Conclusions:

• HIV-infected patients face a high burden of bone demineralization, necessitating vigilance for fragility fractures.
• Understanding the mechanisms of HIV-associated bone loss is crucial for developing targeted interventions.
• Evidence-based recommendations for bone disease screening and treatment in this population are evolving.